This includes monoclonal antibodies such as bevacizumab, which neutralises VEGF following its secretion from tumour cells, and small molecule inhibitors such as pazopanib, which inhibits the intracellular tyrosine kinase domain of VEGFR to prevent downstream signal transduction following VEGF binding. The gene discussed is KDR; the disease is neoplasm.